ClinicalTrials.gov
public full text
Public Domain
Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu
According to previous studies, viral pneumonia can develop into pulmonary fibrosis, which can affect patients'lung function and even life health.This study aims to observe the efficacy and safety of Fuzheng Huayu Tablets in the treatment of pulmonary fibrosis after COVID-19.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Pulmonary fibrosis after COVID-19 is characterized by airway abnormalities and elevated club cell secretory protein-16.#449948
- Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis#1045234
- Integrating Palliative Care for Patients With Idiopathic Pulmonary Fibrosis and Their Caregivers#802631
- Palliative Care Planner (PCplanner)#1125659
- Prophylaxis and Treatment of COVID-19#1186000
Record · ID 1363436
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive